TIDMIXI

RNS Number : 4442N

IXICO plc

08 August 2017

8 August 2017

IXICO plc

("IXICO" or the "Company")

Share option grant

IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the digital technologies company serving neuroscience, announces a grant of options over the ordinary shares in the Company in accordance with the rules of the Company's EMI Share Option Plan 2014 (the 'Plan') exercisable at a price of 34p (being the closing middle market price per ordinary share on 7 August 2017).

The award of options under the Plan is subject to certain performance conditions and the options granted will vest upon the achievement of strategic corporate goals in respect of commercialisation of the Company's products and/or services or a significant corporate development transaction occurring within three years of the date of grant.

The total number of options being issued at this time is 713,940 and includes a grant of options to Susan Lowther, Chief Financial Officer of the Company, as follows:

 
 Name of Director    Number of   Total number       Percentage 
                      options     of options held    of issued share 
                      granted                        capital under 
                                                     option 
------------------  ----------  -----------------  ----------------- 
 Susan Lowther         235,000            545,196              2.01% 
------------------  ----------  -----------------  -----------------

For further information please contact:

 
 IXICO plc 
  Giulio Cerroni, Chief Executive            Tel: +44 20 3763 
  Officer                                    7499 
  Susan Lowther, Chief Financial Officer 
  and Company Secretary 
 Shore Capital (Nomad and Broker)          Tel: +44 20 7408 
  Bidhi Bhoma / Edward Mansfield /James     4090 
  Wolfe 
 
 FTI Consulting Limited (Investor          Tel: +44 20 3727 
  Relations)                                1000 
  Simon Conway/Mo Noonan

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEVLFBDVFLBBL

(END) Dow Jones Newswires

August 08, 2017 11:23 ET (15:23 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ixico Charts.
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ixico Charts.